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Cartilage defects repair poorly. Recent genetic studies suggest that WNT3a may 
contribute to cartilage regeneration, however the dense, avascular cartilage 
extracellular matrix limits its penetration and signaling to chondrocytes. 
Extracellular vesicles actively penetrate intact cartilage. This study investigates 
the effect of delivering WNT3a into large cartilage defects in vivo using exosomes 
as a delivery vehicle.  
Exosomes were purified by ultracentrifugation from conditioned medium of 
either L-cells overexpressing WNT3a or control un-transduced L-cells, and 
characterized by electron microscopy, nanoparticle tracking analysis and marker 
profiling. WNT3a loaded on exosomes was quantified by western blotting and 
functionally characterized in vitro using the SUPER8TOPFlash reporter assay and 
other established readouts including proliferation and proteoglycan content. In 
vivo pathway activation was assessed using TCF/Lef:H2B-GFP reporter mice. 
Wnt3a loaded exosomes were injected into the knees of mice, in which large 
osteochondral defects were surgically generated. The degree of repair was 
histologically scored after 8 weeks. 
WNT3a was successfully loaded on exosomes and resulted in activation of WNT 
signaling in vitro. In vivo, recombinant WNT3a failed to activate WNT signaling in 
cartilage, whereas a single administration of WNT3a loaded exosomes activated 
canonical WNT signaling for at least one week, and eight weeks later, improved 
the repair of osteochondral defects.  
WNT3a assembled on exosomes, is efficiently delivered into cartilage and 
contributes to the healing of osteochondral defects. 
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Key messages 
Chondral and osteochondral regeneration is currently achieved using cell 
preparations, usually autologous, which are expensive and laborious. We reported that 
a single administration of WNT-3A assembled on extracellular vesicles can enhance 
long term osteochondral regeneration. In addition we report that extracellular vesicles 
are an effective vehicle for the delivery of bioactive molecules through the abundant, 
negatively charged and avascular cartilage extracellular matrix. 
 




Cartilage defects are present in 61% of patients undergoing knee 
arthroscopy[1,2], can be disabling, and have the potential to progress into 
osteoarthritis[3]. Cell based approaches to cartilage repair are effective, but, due 
to the largely autologous nature of the transplanted cells, such procedures are 
costly and laborious. A number of novel biological agents are being developed 
which harness and support the endogenous capacity of joint to repair[4]. One 
major limitation in delivering such agents (often macromolecules) is the 
avascular nature of the cartilage tissue and the dense and strongly negatively 
charged extracellular matrix. Antibodies only penetrate the very superficial 
layers[5,6]. Our recent discovery that extracellular vesicles from neutrophils 
actively penetrate cartilage, suggests that extracellular vesicles may be ideal 
vehicles to deliver bioactive molecules to cartilage[7].  
Extracellular vesicles are a heterogeneous group of double membrane bound 
vesicles, ranging in size from 30-400nm, and are synthesized either, through 
direct shedding from the plasma membrane (microvesicles), or by inward 
budding within multi-vesicular bodies (exosomes). They are naturally adapted to 
deliver their contents to cells, can target different tissues, are relatively stable in 
biological fluids and can travel over long distances. Understanding their 
potential and harnessing their targeting ability, would open an abundance of 
therapeutic opportunities in different disease areas and drug delivery[8]. 
As a proof of concept we chose to deliver WNT3a in a model of cartilage 
regeneration, because single nucleotide polymorphisms in the WNT3a gene are 
associated with a reduced regenerative capacity of ear lobe cartilage and because 
of the striking expression pattern of WNT3a at the cartilage regeneration 
front[9].  
WNTs are a family of highly conserved signaling molecules that signal through a 
number of different pathways, including the β-catenin-dependent (canonical 
WNT) pathway, and are known to drive physiological processes including 
developmental morphogenesis, stem cell maintenance and wound 
healing[10,11].  
WNT-β-catenin signaling is activated in response to joint and cartilage 
injury[12]. WNT3a is a strong activator of the WNT-β-catenin pathway[13,14]. In 
healthy cartilage, excessive activation of this pathway results in cartilage 
breakdown[13,15–17]; however following injury, when remodeling and cell 
expansion is necessary to repair tissue, appropriate and timely WNT3a 
upregulation was associated with improved repair[9]. WNTs are insoluble 
molecules that normally adhere to the cell surface through binding to 
heparansulphate proteoglycans. Some WNT molecules, however, can travel long 
distances assembled either with a carrier molecule called SWIM, or attached to 
the surface of exosomes[18].   
Taking advantage of the capacity of WNT3a to be secreted naturally on the 
surface of exosomes we tested the hypothesis that exosomes are an effective 
vehicle to deliver biologically active molecules into cartilage and that exosome 
facilitated delivery of WNT3a would result in a long lasting protective effect and 




Patients or the public were not involved in this research. 
 
Isolation and characterisation of exosomes 
Conditioned medium was generated using serum-free medium containing ITS 
supplement (Sigma I3146), as per the manufacturer's instructions from L-cells 
stably transfected with WNT3a and control L-cells (ATCC® CRL2647™/ 
CRL2648™). Briefly, cells were maintained in complete medium containing 
DMEM/F12 with 10% fetal bovine serum (FBS). L-cells containing WNT3a were 
maintained with 0.4mg/ml G418 for selection. For generation of conditioned 
medium, cells at 80-90% confluency were split in a 1:4 ratio into a new flask and 
cultured for 4 days in DMEM without FBS and containing 1x ITS supplement, 
(G418 was removed from the L-cells containing WNT3a). Medium was then 
removed and replaced with fresh medium for a further 3 days. Both batches of 
medium were then mixed and passed through a 40μm filter before exosome 
isolation.  
Exosomes were isolated as previously described[18]. Briefly, conditioned 
medium was centrifuged sequentially at 300xg, 2000xg and 10,000xg to remove 
dead cells and debris with the supernatant taken forward to the next step. 
Exosomes were concentrated by ultra-centrifugation at 100,000xg for 3 hours. 
The exosome pellet was resuspended in PBS and the ultracentrifugation step 
repeated to wash the exosome preparation, before re-suspending the exosome 
pellet in 200ul of PBS for every 50ml of starting conditioned medium. Particle 
concentration was determined using the NanosightTM, NS300TM for 
nanoparticle tracking analysis. Other validation steps included electron 
microscopy, western blotting and reporter assay. 
 
Western blotting  
For analysis of exosomal preparations, equal volumes or particle concentrations 
were loaded on Tris-Glycine polyacrylamide gels, and transferred to 
nitrocellulose membrane for antibody probing. 
 
Reporter assay 
HEK293 cells were maintained in complete medium described above. Cells were 
plated in monolayer and transfected with SUPER8XTOPFlash TCF/LEF - firefly 
luciferase reporter plasmid (Addgene), using JetPRIME transfection reagent 
(Polyplus). Following 24 hours the medium was changed to serum-free medium 
containing ITS and stimulated for a further 24 hours before collection and 
analysis using Dual luciferase reporter assay system (Promega). 
 
In vitro micromass culture and alcian blue staining for functional analysis 
Human articular chondrocytes (<6 population doublings), were plated in dense 
cultures (2e7cells/ml) to allow matrix deposition. Experiments were conducted 
in serum-free medium containing ITS, over a period of 6 days. For IL-1β 
experiments, micromasses were cultured for 4 days in serum-free medium and 
stimulus added for the final 2 days. Micromasses were then fixed with methanol 
at -20 then stained with 0.5% Alcian blue 8GS (Carl Roth C.l. 74240), over-night. 
The following day the dye was extracted using 8M Guanidine HCL and the 
proteoglycan content quantified using a spectrophotometer[19]. To account for 
any cell proliferation, total proteoglycans were normalised for DNA content. 
 
QPCR for functional analysis 
Human articular chondrocytes (<6 population doublings), were plated in 
monolayer and stimulated under serum-free conditions for 24 hours. RNA was 
extracted from cells using TRIzolTM reagent (Invitrogen 15596026), cDNA was 
then synthesized using oligo(dt) primers (Promega C1101) and SuperscriptTM 
III Reverse transcriptase (Invitrogen 18080093). QPCR analysis was performed 
for the desired genes. Primer sequences are as follows: Actin 5’ 
TGACGGGGTCACCCACACTGTGCCCATCTA and 3’ CTAGAAGCATTTGCGGTGGACGATGGAGG, 
Human Sox9 5’ GAACGCACATCAAGACGGAG and 3’ TCTCGTTGATTTCGCTGCTC, Human Aggrecan 
5’GTTGTCATCAGCACCAGCATC and 3’ACCACACAGTCCTCTCCAGC, Human Col2a1 
5’CTGCTCGTCGCCGCTGTCCTT and 3’AAGGGTCCCAGGTTCTCCATC, Human MMP13 5’ 
ACGGACCCATACAGTTTGAATACAGC and 3’ CCATTTGTGGTGTGGGAAGTATCATC. Human MMP3 
5’ CAACCGTGAGGAAAATCGATGCAG AND 3’ CGGCAAGATACAGATTCACGCTCAA, Human MMP8 
5’GTCATTGTTTCCCATCACTGTATCCATT AND 3’ GGACACAATTCAACCCACGAAACA, Human PCNA 
5’ GGAGAACTTGGAAATGGAAAC AND 3’ CTGCATTTAGAGTCAAGACCC. 
 
In vivo models 
The TCF/Lef:H2B-GFP reporter line was donated by Anna-Katerina 
Hadjantonakis, Memorial Sloan-Kettering Cancer Center[20]. JAX stock #013752. 
For analysis of joint tissue penetration by exosomes, up to 7μl of exosome 
preparation or PBS vehicle was injected intra-articularly in the joints of adult 
transgenic mice expressing green fluorescence protein (GFP) under the control 
of the Tcf/Lef promoter (TCF/Lef:H2B-GFP)[20].  
For analysis of joint tissue repair, ten week old, male C57BL/6 mice were 
anesthetized with isofluorane. A cylindrical defect (0.78+/- 0.042 mm wide and 
1.79+/- 0.056 mm deep) was generated in the lateral femoral condyle using a 
21gauge needle (Thomas, Eldridge et al. manuscript in preparation). Liquid rat 
collagen type 1 gel containing exosomes was injected using a pulled glass pipette 
tip with a diameter of approximately 10µm mounted at the end of a regular 2µl 
pipette tip until the defect was full. The gel solidifies at 37°C. The joint was 
closed with an interrupted suture. After recovery mice were left free to move 
and feed ad libitum in filter cages. The operator and the scorers were blind to the 
treatment. The animals were monitored for signs of suffering and local infection 
at least weekly. Mice were killed 8 weeks after injury and the joints taken for 
analysis. 
 
Staining and immunofluorescence 
Following dissection, mouse knees were fixed overnight with buffered 4% 
paraformaldehyde, then decalcified for 24 hours in formic acid buffer (33% 
formic acid, 13.5% trisodium citrate) at room temperature. Joints were than 
washed with water and embedded in OCT for cryosectioning (at 5μM). For 
proteoglycan analysis, sections were stained with 0.2% Safranin O in acetate 
buffer pH4. Safranin-O intensity was measured by densitometry analysis, 
performed using ImageJ software as previously described[21]. For 
immunofluorescence staining, sections were probed with anti-GFP antibody 
(Abcam ab290). Percentage GFP positive cells were calculated as the percentage 
of fluorescent cells over the total number of cells present in the area analysed. 
The same approach was applied when quantifying the percentage of Ki67 
positive cells, which were fixed with 4% paraformaldehyde and stained with 
Ki67 antibody (Abcam 15580) and dapi. 
 
Ethics 
Animal experiments were conducted under Home Office license 70/7986. 
Human samples were approved and obtained under the East London and the city 
research ethics commitee3 (Rec N.07/Q0605/29). Adult human articular 
cartilage was obtained from patients undergoing joint replacement for knee OA 
after obtaining informed consent.  
 
Statistical analysis 
Parametric data were compared with the t-test, non-parametric data with the 
Mann–Whitney test. Paired analysis was used for in vivo comparisons, where 
controls were contralateral knees. For multiple comparisons, an ANOVA or 
Kruskal-Wallis, including the Tukey’s post-test, was used. P-Values <0.05 were 




WNT3a inhibits specific functions of IL-1β in chondrocytes 
Excessive activation of WNT-β-catenin signaling results in loss of cartilage 
extracellular matrix; nevertheless, WNT3a expression at the injury site facilitates 
repair[9]. We hypothesised that WNT3a may result in different outcomes in 
chondrocytes, depending on whether they are in resting conditions or during 
conditions of challenge. To test this hypothesis we assessed the effect of 
recombinant WNT3a (R-WNT3a), on cartilage catabolism in resting 
chondrocytes and in the presence of an inflammatory stimulus, Interleukin-1β 
(IL-1β). As expected, R-WNT3a treatment of human articular chondrocytes 
(HAC), in micromass culture, resulted in a reduction in proteoglycan content 
(Fig.1A). IL-1β treatment decreased proteoglycan content to an even greater 
extent, however co-treatment with WNT3a lead to a partial rescue of IL-1β -
induced proteoglycan loss (Fig.1A). In keeping with this, R-WNT3a like IL-1β 
caused a loss of chondrocyte markers COL2a1 and AGGRECAN, as well master 
transcription regulator of cartilage, SOX9, but was able to inhibit matrix-
metalloprotease-13 (MMP-13) upregulation caused by IL-1β. Under these 
experimental conditions however, WNT3a did not show the same effect on other 
MMPs upregulated by IL-1β such as MMP-3 and MMP-8 (Fig.1B). These results 
encouraged us to explore the use of WNT3a to support cartilage repair. 
WNT3a is transferred and carried on exosomes  
WNTs are palmitoylated, rendering them insoluble[22]. In order to overcome 
this, and to allow long-distance signaling, endogenous WNTs are secreted from 
cells on the surface of exosomes or associated with other carrier molecules such 
as SWIM [18]. Since we previously demonstrated that extracellular vesicles 
actively enter the cartilage matrix[7], we tested whether we could use 
extracellular vesicles to deliver WNT3a to chondrocytes. This was facilitated by 
the fact that overexpressed WNT3a is spontaneously assembled and secreted on 
the external surface of exosomes as previously demonstrated by electron 
microscopy and immunogold labeling [18,23]. WNT3a-containing exosomes (Ex-
WNT3a) or control exosomes (Ex-C) were purified by ultracentrifugation from 
conditioned medium generated from well-established cell lines, L-cells stably 
expressing WNT3a (L-WNT3a)[18], or from control L-cells (Fig.2). Exosomes had 
the expected shape and size distribution and no major differences were observed 
between the two populations, as assessed by electron microscopy and 
nanoparticle tracking analysis (Fig.2A+B). Although the number of exosome 
batches produced was too low to allow proper statistical analysis, we did not 
observe any differences in size or the ratio of exosomes produced between 
treatments or across different batches of exosomes, generated at different times 
(Fig.2B iii). The exosome preparation contained the exosomal marker TSG101 
(Fig.2C)[18].  WNT3a could be detected on exosomes generated from L-WNT3a 
cells but not on those generated from control L-cells (Fig.2C). By comparison 
with a standard curve generated with known amounts of R-WNT3a, we could 
estimate that the concentration of WNT3a in the exosomal preparation was 
0.0043pg/particle (Fig.2D and Supplementary Fig.1). An equal number of Ex-c 
and Ex-WN3a particles were compared in all functional assays. 
Exosomes can deliver functionally active WNT3a into cartilage in vitro. 
Ex-WNT3a for in vitro experiments were administered in order to dose either an 
estimated 100ng/ml or 50ng/ml of exosome associated WNT3a for comparison 
against the same concentration of recombinant WNT3a. To assess whether 
WNT3a was expressed on exosomes in an active form, we tested whether Ex-
WNT3a could activate the WNT-β-catenin dependent SUPER8TOPFlash reporter 
assay in HEK293 cells. These experiments showed, not only that Ex-WNT3a 
efficiently activated the reporter assay, but that Ex-WNT3a activity was 
maintained also in serum-free conditions. Whereas R-WNT3a was inactive in the 
absence of serum, presumably due to its poor solubility[22] (Fig.3A). This 
suggested that exosomes are efficient carriers for WNTs and deliver them in a 
format that enables signaling. Next we tested whether the exosomal delivery of 
WNT3a modulates its functional activity. We chose the following biological 
outcomes to test: chondrocyte proliferation and reduction of proteoglycan 
content[13]. In vitro, Ex-WNT3a upregulated markers of proliferation, including 
PCNA mRNA and Ki67 protein (Fig.3B+C). Importantly, Ex-WNT3a induced 
greater proliferation than an equivalent amount of the R-WNT3a. This further 
confirms results seen in figure 3A, that WNT molecules do not signal efficiently 
in the absence of serum, but transport on exosomes is able to overcome this 
problem. To validate that Ex-WNT3a had the same protective effects as R-
WNT3a (Fig.1A), we treated HAC micromasses with IL-1β and/or equal 
concentration of Ex-WNT3a. Interestingly Ex-WNT3a alone, did not induce loss 
of proteoglycan of the HAC micromass (Fig.3D). This is in contrast with that seen 
for R-WNT3a (Fig.1A). When administered in combination with IL-1β however, 
which caused a decrease in proteoglycan content, similarly to the recombinant 
protein, Ex-WNT3a resulted in a slight but significant rescue (Fig.3D). 
Exosomes can penetrate cartilage tissue and deliver biologically active 
WNT3a in vivo. 
To assess whether exosomes could deliver active WNT3a into the cartilage 
matrix and signal to chondrocytes in vivo we used a TCF/Lef:H2B-GFP transgenic 
mouse line. These mice express green fluorescence protein (GFP) under the 
control of the Tcf/Lef promoter (TCF/Lef:H2B-GFP)[20]. Since Tcf/Lef is a 
sensitive target of WNT-β-catenin signaling, GFP becomes expressed in cells in 
which signaling is activated. As WNT3a is a potent activator of the WNT-β-
catenin pathway, a strong induction of GFP was expected upon WNT3a delivery. 
Stimulus was administered intra-articularly, to ensure that exosomes reached 
the cartilage within the joint. The joint cavity has a relatively low volume and 
therefore limits the amount of liquid that can be injected (up to 7μl). We 
administered the maximum volume possible to ensure sufficient concentrations 
of WNT3a, which dictated the number of exosomes particles administered. This 
resulted in the administration of an estimated 18ng of WNT3a (4.2e6 particles 
for both Ex-WNT3a and Ex-C) at the 2 day end point, and 44ng of WNT3a (10.1e6 
particles of Ex-WNT3a compared to PBS vehicle) at the 4 and 7 day endpoints. 
44ng of recombinant WNT3a was administered. In vivo, the intra-articular 
injection of Ex-WNT3a in TCF/Lef:H2B-GFP reporter mice (Fig.4A) resulted in 
the activation of WNT-β-catenin signaling within the full thickness of the 
articular cartilage and menisci as assessed by immunofluorescence for GFP 
(Fig.4B). Importantly the same concentration of R-WNT3a, failed to activate the 
GFP reporter (Fig.4C). In keeping with the known capacity of WNT3a to reduce 
glycosaminoglycan in cartilage tissue[13], Safranin-O staining was reduced in the 
cartilage of mice treated with Ex-WNT3a, 7 days post injection (Fig.4D). 
Exosomes loaded with WNT3a improved osteochondral repair in mice. 
WNT3a is genetically associated with the capacity to repair the ear lobe in 
mice[9]. To investigate if Ex-WNT3a enhanced the repair of osteochondral 
defects in the knee, we generated critical-size osteochondral defects on the 
lateral femoral condyle of adult mice and filled it with rat collagen type1 gel 
containing either Ex-WNT3a or Ex-C (Fig.5A). As with previous in vivo 
investigations (Fig.4) we administered the maximum number of particles 
possible into the volume of the defect, resulting in an estimated 5ng of WNT3a 
delivered (1.2e6 particles for both Ex-C and Ex-WNT3a). Eight weeks later, joints 
treated with Ex-WNT3a had an improved repair score (measured by the Pineda 
score[24]), when compared to joints treated with Ex-C (Fig.5B+C). Histological 
images show an overview of the joint (Fig.5B), a higher magnification of the 
cartilage surface in the region of the defect (Fig.5B i), and a higher magnification 
of the synovial lining (Fig.5B ii), which at this late endpoint, showed no 
hyperplasia/ thickening of the synovial lining. In a second experiment, we 
repeated the defect and treatment regime but this time terminated at only 3 days 
post injury to assess the situation in the joints during the early phases of repair. 
No visible histological differences were observed at this stage, between joints 
treated with either Ex-C or Ex-WNT3a (representative images shown in 
supplementary figure 2). However cartilage surface/joint damage, consistent 
with the early phases following injury, were observed in all joints and are 
represented in Fig.5D. Histological images show an overview of an injured knee 
joint, with insets showing damaged cartilage/ subchondral bone tissues in the 
outer regions of the defect (Fig.5 i), cartilage surface fibrillation in regions of the 
joint away from the defect (Fig.5 ii), and thickening of the synovial lining (Fig.5 
iii), consistent with the expected inflammation present at this early stage 




We have shown that the use of exosomes as a vehicle enables the delivery of 
WNT3a into the avascular cartilage in a biologically active form and promotes 
the healing of critical size osteochondral defects in mice.  
 
Chondrocytes are encased in a dense, negatively charged, avascular extracellular 
matrix, which is poorly permeable to macromolecules. For instance, antibodies 
do not penetrate the cartilage extracellular matrix[25] and even antigen binding 
fragments only enter the very superficial layers[26]. In addition, WNT molecules 
are relatively insoluble[27] and bind to heparansulphate proteoglycans which 
can further reduce their passive diffusion into cartilage. In view of this, it is not 
surprising that the injection of recombinant WNT3a did not elicit a signaling 
response.  
 
In contrast, we have provided evidence that exosomes achieve efficient and 
prolonged delivery of this particularly challenging molecule, into the full depth of 
the cartilage. This represents a technological breakthrough for several molecular 
targets that have been validated using transgenic approaches in repair as well as 
in osteoarthritis[28–36], but where the efficient delivery of a recombinant 
protein is an obstacle towards clinical application.  
 
Extracellular vesicles have the advantage over synthetic carriers such as 
liposomes or capsules in that they have active mechanisms of motility and 
homing. For instance, extracellular vesicles, but not capsules of the same size 
could penetrate the avascular cartilage extracellular matrix and reach 
chondrocytes[7]. In recent years the potential of exosomes as delivery vehicles 
has been well recognized and interest from the pharmaceutical industry has 
soared resulting in technological advancements in the field. These include 
breakthroughs in loading and delivery of cargo[37] as well as improvements and 
up scaling for production and purification. In this study we chose 
ultracentrifugation for exosome preparation, this is in adherence with previous 
reports studying the secretion of WNTs on exosomes[18,23]. Although widely 
used, when considering large scale production and preparation, limitations such 
as the co-isolation of non EV materiel and the tedious nature of the technique for 
low recovery of product, makes the method unsuitable. Novel and improved 
technologies, will therefore be essential when considering exosomes for therapy. 
In addition to production, challenges in bringing these novel EV based 
therapeutics to the clinic will also need to be overcome. It is likely that given 
their cellular origin and complex composition, they will require an approach 
similar to that of cell based therapies[38]. Never the less, utilizing and expanding 
on this opportunity to overcome challenges in delivering therapy to cartilage, in 
the future could lead to safe and efficient production of exosomes from validated 
cell lines for delivery of even large complicated molecules, thus removing one of 
the biggest challenges in treating cartilage injury.   
 
We previously showed that extracellular vesicles actively penetrate the cartilage 
extracellular matrix[7]. It is not clear whether this active penetration is due to 
adhesion properties and motility or whether the extracellular vesicles follow 
chemotactic cues. Here we showed the successful delivery of a WNT3a signal by 
exosomes, to chondrocytes within their extracellular matrix, however, we did 
not demonstrate that the exosomes physically enter the matrix and reach the 
chondrocyte cell membrane. It is therefore also possible that WNTs are released 
from the exosomes before entering cartilage or that they trigger relay 
mechanisms. The delivery of WNT3a on exosomes led to a surprisingly long-
lasting signaling response, suggesting that the exosomes not only conferred 
WNT3a signal into the cartilage, but also may prolong the local half-life.  
 
It is important to highlight how a single delivery of exosomal WNT3a was 
sufficient to improve repair, which was evident 8 weeks later. We did not 
observe any differences between Ex-WNT3a and Ex-C treated knees at 3 days 
post injury, and therefore, cannot confirm a precise mechanism of action for Ex-
WNT3a in joint repair. It is possible that the huge endogenous response 
occurring in the joint following injury, could mask differences between 
treatments. Considering the biology of WNT3a, and our WNT pathway activation 
data in healthy mouse knees (Fig.4), we can hypothesise that the long-lasting 
effect was due to the retention of WNT3a in an active form for prolonged or 
increased signaling. It is also possible that a relatively short signaling event by 
WNT3a may have triggered homeostatic effects that are self-maintained or lead 
to long-term outcomes. This is suggested by the fact that a single, short episode 
of activation of β-catenin led to the formation of thicker cartilage in mice[39].  
 
Whereas there is abundant literature covering the genetics of osteoarthritis, the 
genetics of repair are understudied. A recent publication identified a single 
nucleotide polymorphism in the Wnt3a locus which was associated with the 
capacity of mouse sub-strains to repair punch-holes in the ear pinna[9]. In 
keeping with a direct function in repair mechanism, WNT3a protein was more 
strongly expressed at the healing edge of the ear cartilage in mouse strains that 
healed better. This, and the capacity of WNT3a to profoundly modulate the 
chondrocyte phenotype[13] motivated our choice for this target.  
 
Our data show that WNT3a was able to drive an improved repair following joint 
injury (figure 5). In spite of this, and the genetic evidence supporting a positive 
role of WNT3a in cartilage repair and its well-known capacity to support 
cartilage stem cells[14], WNT3a is also known to mediate catabolic functions 
such as loss of extracellular matrix components (figure 1 and reference[13]).  
This apparent paradox is explained by the fact that joint surface repair requires a 
sequence of events in a precise, tightly regulated temporal order. The early 
phases immediately after injury are characterized by expansion of stem cell 
populations[3,40] and extracellular matrix remodelling[3,12,41]. The late 
phases, instead, are characterized by tissue patterning followed by extracellular 
matrix synthesis and maturation[42]. The choice of therapeutic agents to 
enhance repair, therefore, will need to be targeted to the specific repair phase. In 
this context, we chose to deliver WNT3a in the early phase of repair when matrix 
remodeling and cell proliferation are required to replace damaged cells and 
tissues, rather than in the later phases when WNT3a may result in detrimental 
effects such as loss of proteoglycans. In healthy cartilage WNT signaling needs to 
be maintained to a minimum, whereas cartilage injury triggers a transient wave 
of WNT activation[12,43] which is required to support local progenitor cells 
[39]. Therefore, while administering WNT3a to recently injured cartilage 
reinforced a naturally occurring repair mechanism which ultimately led to 
increased proteoglycan content, its administration in healthy cartilage triggered 
a early, likely transient, matrix remodeling, which would be useful during the 
early phases of repair, but is undesirable in homeostatic conditions. 
 
In keeping with this observation, in our experiments, recombinant WNT3a had a 
dramatically different effect in healthy cartilage (in which it drove the loss of 
extracellular matrix), compared to inflammatory conditions (in which it reduced 
the capacity of IL-1β to cause loss of proteoglycans) (figure 1). Interestingly, 
unlike recombinant WNT3A, WNT3A associated to exosomes did not result in 
proteoglycan loss in chondrocyte micromasses (figure 3D). While we do not have 
experimental data do explain this discrepancy, it is possible that the context of 
WNT3a presentation when assembled on exosomes may modify its affinity to its 
receptors and bias its signaling properties. Alternatively, the bioavailability of 
WNT3a assembled on exosomes may be different or be associated with different 
temporal dynamics compared to the naked recombinant protein. 
 
Although, in our murine injury model, we could measure a statistically significant 
improvement of the repair outcome, the quality of the healed cartilage was not 
optimal. This could be due to different factors, including the size of the defect, 
which might be too large to achieve full repair, the dose of WNT3a, the time and 
frequency of administration, and the choice of the bioactive molecule being 
delivered. In this context, although our choice of WNT3a was justified by genetic 
evidence, other WNTs such as WNT16, which supports production of the joint 
lubricant, Lubricin[21], have shown perhaps a better pharmacological profile. 
Nevertheless, this study represents a unique proof of concept that supporting the 
early phases of repair has long term beneficial outcomes. This study also 
represents a proof of concept for this technology. The choice of the ligand, the 
generation of appropriate cell lines for exosome generation, and safe, optimal, 
consistent delivery, will be paramount for the clinical application. 
 
In this study we have demonstrated that a single administration of WNT3a, a 
molecule upregulated by acute cartilage injury, enhances the long-term outcome 
of cartilage repair. This highlights the importance of the early phases of injury 
response in priming the repair cascade. In addition, we have demonstrated that 
exosomes are able to deliver functionally active molecules into joint tissues, 
resulting in long lasting and protective effects. This presents a unique 
opportunity to harness the natural targeting power of exosomes for the benefit 
of therapy delivery across medicine. 
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FIGURE LEGENDS 
Figure 1: A) HAC micromasses were treated with combinations of recombinant 
WNT3a (50ng/ml R-WNT3a) and IL1-β (10ng/ml) over 6 days, then stained with 
alcian blue (Ab) dye to assess proteoglycan content, which was normalised to 
DNA content to account for proliferation (n=4). B) HAC were treated with IL1-β 
(10ng/ml) and R-WNT3a (100ng/ml) and mRNA readouts of cartilage anabolism 
and IL1-β pathway activation assessed by QPCR after 24 hours (n=4).  
 
Figure 2: A) Electron microscopy of Ex-WNT3a and Ex-C. Includes an overview 
and zoomed in images. Scale bars on all images represent 0.2μm. B i and ii) 
Nanoparticle tracking analysis of representative Ex-WNT3a and Ex-C 
preparations using NanosightTM(NS300). B iii) Comparison of number of 
particles and modal size of the particles (nm) for both Ex-C and Ex-ENT3a across 
different batches. C) Western blot for WNT3a and Tsg101 (exosomal marker) of 
20ul of supernatant (SNo) and exosome pellet/fraction (Ex fract) of L-WNT3a 
and control L-cells, following 100,000xg ultracentrifugation (n=2). D) Western 
blot for WNT3a using a standard curve of R-WNT3a ([Rec]) and varying amounts 
of Ex-WNT3a ([Ex]) to determine concentration of WNT3a in exosome 
preparation (n=3). Detailed explanation in supplementary figure 1.  
 
Figure 3: A) SUPER8TOPFlash reporter assay in HEK293 cells comparing R-
WNT3a and Ex-WNT3a, both serum and serum-free conditions (estimated 
100ng/ml WNT3a, n=4). B) HAC were treated with Ex-WNT3a, Ex-C, R-WNT3a 
or PBS, for 24 hours in serum-free conditions (estimated 100ng/ml WNT3a). 
QPCR for PCNA mRNA was conducted (n=4). C) HAC from two separate donors, 
were treated with Ex-WNT3a (50ng/ml) and equal concentration of R-WNT3a 
for 24 hours in serum-free conditions. Cells were stained for Ki67 protein to 
assess cell proliferation (n=8 per donor). Representative pictures for Ki67 
analysis shown below. D) HAC micromasses were treated with combinations of 
Ex-WNT3a (50ng WNT3a protein) and IL1-β (10ng/ml) over 6 days in serum-
free conditions, then stained with alcian blue dye to assess proteoglycan content 
(n=4). 
 
Figure 4: A) Immunofluorescence for GFP in TCF/Lef:H2B-GFP reporter mice 
injected intra-articularly with Ex-WNT3a or Ex-C (representative images from 
the 2 day end point). B) Quantification of immunofluorescence for GFP in 
TCF/Lef:H2B-GFP mice injected with Ex-WNT3a or control and killed after 2, 4 
and 7 days (n=4 per time point). For the 2-day end point, Ex-WNT3a containing 
18ng of WNT3a was compared to an equal particle number of Ex-C (4.2e6 
particles). In the 4 and 7-day end point, Ex-WNT3a containing 44ng of WNT3a 
(10.1e6 particles) was compared to contralateral control knees injected with PBS 
vehicle. C) Additional reporter mice were injected with 44ng of WNT3a 
recombinant and compared to their contralateral controls. D) Safranin-O staining 
of mice injected with Ex-WNT3a (containing 44ng of WNT3a) or PBS and killed 7 
days later (n=4).  
 
Figure 5: An osteochondral defect was generated in the lateral femoral condyle 
and filled with 2μl of rat collagen type1 gel, containing treatment. A) Scheme of 
joint injury model, including images of time 0 and 8 weeks post injury (WPI) 
without treatment. B) Defects were treated with either Ex-WNT3a (estimated 
5ng WNT3a protein) or Ex-C (equivalent number of particles, 1.2e6 particles per 
knee) at time 0 and the experiment was terminated at 8 WPI (n=7 for Ex-C and 
n=5 for Ex-WNT3a). Knees were sectioned and stained with Safranin-O. Defect 
margins are depicted by black brackets in over view images. Higher 
magnification images are shown in i (defect area at cartilage surface) and ii 
(synovium), with black arrows indicating synovial lining. C) Repair was assessed 
using the Pineda score at 8 WPI. D) Additional mice were treated exactly as in 
the 8 week experiment and instead terminated at 3 days post injury to assess the 
early phases of repair. Images show an overview of the injured joint and insets at 
a higher magnification: i) showing the cartilage surface in the area of the defect, 
ii) showing fibrillation on the cartilage surface away from the defect, and iii) 


















Supplementary figure 1: To calculate the concentration of WNT3a in the 
exosomes, different concentrations of R-WNT3a were run on a western blot and 
the band density was calculated to generate a standard curve. On the same blot, 
Ex-WNT3a was also run and the concentrations extrapolated using the standard 
curve. Three different exposures were generated for the blot and the most 
appropriate was selected for concentration analysis. Variance is represented as 












ng of WNT3a loaded
Volume Exosome 
preparation loaded






Average ng/μl 7.4 (+/- 1.51)
Particle concentration 1700000/μl
ng of WNT3a per particle 4.34E-06
0.00434 pg of wnt3a per particle
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